1. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia
   Ayman A.M. Alameen et al, 2016, Oncotarget CrossRef
2. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other “Shock” Drugs
   Erik Abner et al, 2018, Journal of Virology CrossRef
3. Specific inhibition of DPY30 activity by ASH2L-derived peptides suppresses blood cancer cell growth
   Kushani K. Shah et al, 2019, Experimental Cell Research CrossRef
4. In Vitro Study of Cytotoxic Mechanisms of Alkylphospholipids and Alkyltriazoles in Acute Lymphoblastic Leukemia Models
   Larissa de Oliveira Passos Jesus et al, 2022, Molecules CrossRef
5. C‑Myc inhibitor 10058‑F4 increases the efficacy of dexamethasone on acute lymphoblastic leukaemia cells
   Mei Lv et al, 2018, Molecular Medicine Reports CrossRef
6. Hijacking a key chromatin modulator creates epigenetic vulnerability for MYC-driven cancer
   Zhenhua Yang et al, 2018, Journal of Clinical Investigation CrossRef
7. C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4
   Negar Sheikh‐Zeineddini et al, 2020, European Journal of Pharmacology CrossRef
8. Synthesis of 5-(Het)arylidene-3-[2-(4-hydroxyphenyl)ethyl]-2-thioxothiazolidine-4-one Derivatives and Study of Their Antitumor and Anti-Inflammatory Activity
   V. Ya. Horishny et al, 2020, Russian Journal of General Chemistry CrossRef
9. The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells
   Carolina Simioni et al, 2015, Oncotarget CrossRef